AKTX Insider Trading Activity and SEC Form 4 Filings
AKTX insider trading summary
No open-market insider purchases or sales of Akari Therapeutics Plc (AKTX) have been reported on SEC Form 4 in the past 12 months.
Latest AKTX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 25, 2025 | Abizer Gaslightwala | CEO | Buy | $3K (3,000 @ $0.90) |
| Aug 22, 2025 | Abizer Gaslightwala | CEO | Buy | $7K (8,000 @ $0.93) |
| Aug 21, 2025 | Abizer Gaslightwala | CEO | Buy | $9K (10,000 @ $0.94) |
| Jun 24, 2025 | Abizer Gaslightwala | President & CEO | Buy | $6K (5,203 @ $1.16) |
| Jun 23, 2025 | Abizer Gaslightwala | President & CEO | Buy | $1K (943 @ $1.15) |
| Jun 20, 2025 | Abizer Gaslightwala | President & CEO | Buy | $12K (10,000 @ $1.20) |
| Jun 17, 2025 | Abizer Gaslightwala | President & CEO | Buy | $18K (15,000 @ $1.20) |
| Sep 18, 2015 | Mark S Cohen | Director | Buy | $200K (1,055,600 @ $0.19) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.